ArticleBioMed research international2026
Evaluation of LncRNA NEAT1 and MEG3 Expression Levels in Hospitalized COVID-19 Patients.
Article in BioMed research international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of LncRNA NEAT1 and MEG3 Expression Levels in Hospitalized COVID-19 Patients.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe novel coronavirus known as SARS-CoV-2 was initially discovered in Wuhan, China, in December 2019, as the cause of COVID-19, according to the World Health Organization in March 2020. Today, the role and function of LncRNAs in the pathogenesis of viral diseases and their diagnosis and treatment have been widely investigated. This study is aimed at evaluating the expression levels of LncRNA NEAT1 and LncRNA MEG3 in hospitalized COVID-19 patients compared to healthy controls.
methodsThis study is a case-control. Patients' serum samples were taken from patients with COVID-19 hospitalized in the covid department of Razi Hospital in Ahvaz, as 30 serum samples from healthy people served as the control group and the case group. RNA extraction was performed for all samples. Then, the expression level of LncRNA NEAT1 and LncRNA MEG3 genes in COVID-19 patients and the control group was done using real-time PCR technique. Finally, all the obtained results were analyzed using REST software.
resultsAccording to the obtained results, the case group's LncRNA NEAT1 gene expression level was higher than that of the control group, was not significant (p = 0.217), and COVID-19 patients' LncRNA MEG3 gene expression was reduced in COVID-19 patients compared to controls (p = 0.001).
conclusionThe expression of LncRNA MEG3 was significantly downregulated in COVID-19 patients (p = 0.001), suggesting its potential role in viral immune evasion. Although LncRNA NEAT1 expression was elevated in patients, this increase was not statistically significant (p = 0.217). Therefore, only LncRNA MEG3 appears to be a promising biomarker for COVID-19 progression, whereas the role of LncRNA NEAT1 requires further investigation in larger cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.